徐小薇,王跃明,李大魁

• 1:中国医学科学院-中国协和医科大学北京协和医院药剂科!北京100730
• 2:中国医学科学院-中国协和医科大学医药生物技术研究所药理研究室!北京100050
• 3:中国医学科学院-中国协和医科大学北京协和医院药剂科!北京100730

摘要(Abstract)：

关键词(KeyWords)：

Abstract:

Keywords:

基金项目(Foundation):

作者(Author): 徐小薇,王跃明,李大魁

DOI: 10.19577/j.cnki.issn10074406.2001.02.028

参考文献(References)：

• [1]金有豫 .药物的体内过程与转运和转化及其儿科的特点 .见 :李文汉 ,胡仪吉 .儿科临床药理学 ,第 1版 .北京 :人民卫生出版社 ,1998,16～ 2 2
• [2 ] Reed MD. Principles of drug therapy. In:Behrman RE,Klegman RM,Nelson WE.Nelson Textbook of Pediatric.Philadophia:WB Saunder Company,1996 ,2 5 2 -2 5 8
• [3]赵时敏 .新生儿疾病的药物治疗 .见 :北京协和医院临床药物组 .疾病的临床药物治疗 ,第 1版 .北京 :中国医药科技出版社 ,1987,377～ 379
• [4]周元晏 .磺胺类及呋喃类等抗菌药 .见 :杨藻宸 ,江明性 .医用药理学 ,第 3版 .北京 :人民卫生出版社 ,1997,888～ 889
• [5 ] Boreus L O .The role of therapeutic drug monitoring inchildren.Clin Pharmacokinet,1989,17(Suppl 1) :4
• [6 ] Gilman JT. Therapeutic drug m onitoring in the neonate andpaediatric age group.Clin Pharmacokinet,1990 ,19(1) :1
• [7] Aranda JV.Factors associated with adverse reactions in thenewborn.Pediatric Phamacol,1983,3:2 45
• [8]周森麟 .儿科药物不良反应监察和处置 .中国临床药学杂志 ,1999,8(1) :5 5
• [9] L andier M.Hearing loss related to ototoxity in children withcancer.JPediatr Nur,1998,15 (4 ) :195
• [10 ] Housman F D,L edley D.Why pharmacogenom ics?Why now?Nat Biotechnol,1998,16 (6 ) :492
• [11] Gilman JT,Gal P.Pharmacokinetic and pharmacodynamicdata collection in children and neonate. ClinicalPharmacokinetics,1992 ,2 3(1) :1
• [12 ] FDA. Guidance for Industry:general consideration forpediatric pharmacokinetic studies for drugs and biologicalproduct,1998,11
• [13] Murphy JE,Pedltier T,Anderson D.A comparison of venousversus capillary measurements of drug concentration.TherDrug Monit,1990 ,12 (3) :2 6 4
• [14 ] Kauffman RE,Kearns GL.Pharm acokinetic studies inpediatric patients.Clin Pharmacokinet,1992 ,2 3(1) :10
• [15 ] Chiriboga CA,Brust JCM,Bateman D.Dose-response effectof fetal concaine exposure on newborn neurologic function.Pediatrics,1999,10 3(1) :79
• [16 ] Levitsky LL,Schoeller DA,L ambert GH,et al.Effect ofgrowth horm one therapy in growth horm one-defiecientchildren on cytochrome P-4 5 0 -dependent3-N-dem ethylationof caffeine as measured by the caffeine1 3 CO2 breath test.DevPharmacol Ther,1989,12 :90
• [17] Zarowitz BJ,Peterson E,Popovich J Jr.Relationship ofbioelectrical impedance to pharmacokinetic parameters oftheophylline in health males.Clin Pharmacokinet,1989,17(3) :2 0 0
• [18] Pilla AM,Zarowitz BJ,Svensson CK,et al.Bioimpedanceassessment of antipyrine pharmacokinetics before and afterenzyme induction.Drug Intell Clin Pharm,1990 ,2 4(6 ) :5 75
• [19] Jynge P,Kleinbloesem ST,et al.In vivo tissuepharm acokinetics by fluorine magnetic resonancespectroscopy:a study of liver and muscle disposition offleroxaxin in hum ans.Clin Pharmacol Ther,1990 ,48(5 ) :481
• [2 0 ] FDA.Draft list published of drugs needing pediatric data.http:∥ www.fda.gov,1998,3